Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Review

Hans-Peter Horny1

  • 1University of Lübeck, Lübeck, Germany.

Clinical Advances in Hematology & Oncology : H&O
|September 16, 2005
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mast Cell Activation Syndrome: Quantification of Mast Cells Across Conditions Reveals Limited Diagnostic Utility of Mast Cell Counts and Tryptase Depletion Index.

Archives of pathology & laboratory medicine·2026
Same author

Leukocytosis, Monocytosis, and Eosinophilia in Systemic Mastocytosis: Analysis of Phenotype, Genetics and Prognosis in 596 Patients From the GREM Registry.

The journal of allergy and clinical immunology. In practice·2025
Same author

Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts.

American journal of hematology·2025
Same author

The number of vertebral fractures in indolent systemic mastocytosis is influenced by presence of the KIT-mutation.

Bone·2025
Same author

Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM.

The journal of allergy and clinical immunology. In practice·2024
Same author

Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in <i>KIT</i> D816V-Negative Advanced Systemic Mastocytosis.

Cancers·2024
Same journal

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Active treatment in high-risk, early-stage CLL or SLL.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting human kallikrein 2 in prostate cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting BRAF V600E mutations in metastatic colorectal cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

The development of second-generation KRAS inhibitors.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026
See all related articles